Prostate cancer—a malignancy arising from the epithelial cells of the prostate gland—is the second most frequently diagnosed cancer in men worldwide and a major cause of cancer death within genitourinary (GU) oncology. Located directly below the bladder and surrounding the proximal urethra, the prostate gland plays a central role in male reproductive physiology by secreting fluid that nourishes and transports sperm.
Because prostate tissue growth and function are heavily dependent on male sex hormones (androgens), prostate cancer exhibits a distinct biological profile compared to other solid tumors. The clinical course of prostate cancer spans a broad spectrum: ranging from indolent, low-risk tumors that pose minimal risk over a patient’s lifetime to aggressive, highly metastatic disease that requires comprehensive multimodal intervention.
1. Pathophysiology and Genomic Drivers
Prostate carcinogenesis is driven by an accumulation of genetic alterations, cellular stress, and hormonal signaling changes within the glandular epithelium. Over 95% of primary prostate cancers are classified histologically as acinar adenocarcinomas, originating predominantly within the peripheral zone of the gland.
[ Normal Prostatic Epithelium ]
│
(Prostatic Intraepithelial Neoplasia - PIN)
│
▼
[ Primary Adenocarcinoma ]
│
┌──────────────────────────┴──────────────────────────┐
▼ ▼
[ Localized / Castration-Sensitive ] [ Advanced / Castration-Resistant ]
• Dependent on Androgen Receptor (AR) • AR Amplification / Splice Variants (AR-V7)
• Response to Androgen Deprivation (ADT) • DNA Damage Repair Mutations (BRCA1/2, ATM)
The Central Role of Androgen Receptor (AR) Signaling
The development and maintenance of prostatic tissue depend on circulating androgens—primarily testosterone and its more potent metabolite, dihydrotestosterone (DHT). DHT binds to intracellular Androgen Receptors (AR), which translocate to the cell nucleus to trigger gene transcription supporting cellular proliferation and survival. In early and localized stages, prostate cancer remains castration-sensitive, relying heavily on this signaling axis.
Genomic Landscape and Driver Alterations
Advances in molecular profiling have identified key genetic drivers across various stages of prostate cancer:
- TMPRSS2-ERG Gene Fusion: Found in approximately 50% of primary prostate tumors, placing the ERG oncogene under the control of the androgen-responsive TMPRSS2 promoter.
- Tumor Suppressor Loss: Deletions or mutations in PTEN (activating the pro-survival PI3K/Akt/mTOR pathway) and TP53 correlate with disease progression and therapeutic resistance.
- DNA Damage Repair (DDR) Defects: Germline or somatic mutations in homologous recombination repair genes—such as BRCA2, BRCA1, and ATM—occur in up to 20–25% of metastatic castration-resistant prostate cancers (mCRPC), opening pathways for targeted therapies.
2. Risk Factors, Screening, and Early Detection
Identifying prostate cancer early requires balancing the benefits of detecting aggressive disease against the risks of overdiagnosing indolent tumors.
Epidemiology and Risk Drivers
- Age: The primary non-modifiable risk factor; incidence increases sharply after age 50.
- Ethnicity: Men of African descent experience significantly higher incidence rates and present at younger ages with more aggressive disease compared to other ethnic groups.
- Family History and Genetics: A strong family history or carrier status for BRCA2 or Lynch syndrome markedly increases individual lifetime risk.
Screening Methodologies
- Prostate-Specific Antigen (PSA) Testing: PSA is a glycoprotein enzyme produced by prostatic epithelial cells. While serum PSA elevation (>4.0 ng/mL) can indicate prostate cancer, it is tissue-specific rather than cancer-specific. PSA levels also rise due to benign prostatic hyperplasia (BPH), prostatitis, or mechanical trauma.
- Digital Rectal Examination (DRE): Physical palpation of the posterior and lateral aspects of the prostate to assess for nodules, asymmetry, or induration.
- Multiparametric MRI (mpMRI): High-resolution MRI before biopsy evaluates suspicious lesions using the PI-RADS (Prostate Imaging-Reporting and Data System) scoring system (grades 1–5), improving biopsy precision and reducing unnecessary procedures.
- Targeted Biopsy: Fusion of mpMRI images with real-time transrectal or transperineal ultrasound (TRUS) allows targeted core needle biopsy of specific suspicious regions.
3. Grading, Staging, and Risk Stratification
Accurate risk assignment guides therapeutic decisions, ensuring aggressive cancers receive prompt intervention while low-risk cases avoid unnecessary treatment toxicity.
| Histological Grade | Grade Group | Primary + Secondary Pattern | Clinical Aggressiveness Profile |
|---|---|---|---|
| Gleason 6 | Grade Group 1 | 3+3=6 | Low risk; candidate for Active Surveillance |
| Gleason 7 | Grade Group 2 / 3 | 3+4=7 (Group 2) / 4+3=7 (Group 3) | Favorable (Group 2) vs. Unfavorable (Group 3) Intermediate |
| Gleason 8 | Grade Group 4 | 4+4=8 | High risk; aggressive local/systemic therapy |
| Gleason 9–10 | Grade Group 5 | 4+5, 5+4, or 5+5 | Very high risk; rapid progression tendency |
Staging and Advanced Molecular Imaging
Staging uses the TNM system (Tumor size/extent, Node status, Metastasis). While conventional staging relies on CT and bone scans, modern staging frequently incorporates PSMA PET/CT (Positron Emission Tomography targeting Prostate-Specific Membrane Antigen). PSMA PET/CT provides high sensitivity for detecting microscopic nodal and bone metastases even at low PSA levels.
4. Therapeutic Management Across Clinical Stages
Treatment strategies are dictated by risk category, anatomical stage, overall health, and personal goals.
[ Risk-Stratified Diagnosis ]
│
┌─────────────────────────────────┼─────────────────────────────────┐
▼ ▼ ▼
[ Low Risk (GG1) ] [ Intermediate / High Risk ] [ Metastatic / Advanced ]
• Active Surveillance • Radical Prostatectomy • Androgen Deprivation (ADT)
• Serial PSA & mpMRI • Radiation + Short/Long ADT • AR Signaling Inhibitors (ARSI)
• Re-biopsy protocols • Pelvic Lymphadenectomy • Radioligand / PARP Inhibitors
Localized Disease Management
- Active Surveillance: The standard of care for low-risk (Grade Group 1) prostate cancer. Patients avoid immediate surgery or radiation, undergoing serial PSA testing, repeat mpMRI, and periodic biopsies to intervene only if disease progression occurs.
- Radical Prostatectomy: Surgical excision of the entire prostate gland and seminal vesicles (often with pelvic lymph node dissection), performed via minimally invasive robot-assisted laparoscopic surgery.
- Radiation Therapy: External Beam Radiation Therapy (EBRT) or Brachytherapy (interstitial seed implantation), often combined with transient Androgen Deprivation Therapy (ADT) for intermediate and high-risk cases.
Advanced and Metastatic Disease Management
When prostate cancer extends beyond local surgical boundaries or metastasizes (predominantly to axial skeleton bones and distant lymph nodes), systemic therapy is required:
- Androgen Deprivation Therapy (ADT): Surgical castration (orchiectomy) or chemical castration via LHRH agonists/antagonists (e.g., leuprolide, degarelix) lowers serum testosterone to castrate levels (<50 ng/dL).
- Novel AR Pathway Inhibitors (ARSI): Next-generation agents—such as abiraterone acetate, enzalutamide, apalutamide, and darolutamide—block androgen synthesis or directly inhibit AR binding, improving overall survival in both metastatic castration-sensitive and castration-resistant settings.
- Targeted Radioligand Therapy: 177Lu-PSMA-617^{177}\text{Lu-PSMA-617}177Lu-PSMA-617 delivers targeted beta-particle radiation directly to PSMA-expressing prostate cancer cells throughout the body.
- PARP Inhibitors: Olaparib and rucaparib offer targeted therapy for patients with metastatic castration-resistant disease harboring homologous recombination repair (HRR) gene mutations (e.g., BRCA1/2).
Conclusion
Genitourinary prostate cancer management has entered an era of precision medicine. From risk-adapted active surveillance and mpMRI-guided biopsies to PSMA-targeted radioligand therapies and genomic biomarker profiling, modern clinical care balances effective cancer control with patient quality of life. Continued multidisciplinary collaboration ensures that therapy remains tailored, precise, and effective across all disease stages.